Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

被引:135
|
作者
Nolan, D
Upton, R
McKinnon, E
John, M
James, I
Adler, B
Roff, C
Vasikaran, S
Mallal, S [1 ]
机构
[1] Royal Perth Hosp, Dept Clin Immunol, Ctr Clin Immunol & Biomed Stat, Perth, WA 6000, Australia
[2] Murdoch Univ, Murdoch, WA 6150, Australia
[3] Royal Perth Hosp, Dept Nucl Med, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA, Australia
关键词
bone mineral density; HAART; indinavir; lipodystrophy syndrome; nelfinavir; protease inhibitors; osteopenia; osteoporosis; subcutaneous fat wasting;
D O I
10.1097/00002030-200107060-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients. Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04). Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between P1 therapy and decreased lumbar spine z-score. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1275 / 1280
页数:6
相关论文
共 50 条
  • [1] Nephrolithiasis in HIV-infected patients treated with indinavir
    Rodriguez-Rosado, R
    Jimenez-Nacher, I
    Valencia, E
    Soriano, V
    Gonzalez-Lahoz, JG
    ANTIVIRAL THERAPY, 1998, 3 (02) : 113 - 113
  • [2] Bone mineral density evolution in HIV-infected patients
    Torralba, M
    Azriel, S
    Rubio, R
    Tamargo, L
    Moreno, V
    Pulido, F
    Jódar, E
    Hawkins, F
    ANTIVIRAL THERAPY, 2003, 8 (04) : L95 - L96
  • [3] Management of bone mineral density in HIV-infected patients
    Negredo, Eugenia
    Bonjoch, Anna
    Clotet, Bonaventura
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (06) : 845 - 852
  • [4] Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients
    Cervero, Miguel
    Torres, Rafael
    Luis Agud, Jose
    Alcazar, Victoria
    Jose Jusdado, Juan
    Garcia-Lacalle, Concepcion
    Moreno, Santiago
    PLOS ONE, 2018, 13 (04):
  • [5] Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years
    Bolland, Mark J.
    Grey, Andrew B.
    Horne, Anne M.
    Briggs, Simon E.
    Thomas, Mark G.
    Ellis-Pegler, Rod B.
    Woodhouse, Andrew F.
    Gamble, Greg D.
    Reid, Ian R.
    CLINICAL ENDOCRINOLOGY, 2007, 67 (02) : 270 - 275
  • [6] Tools to predict low bone mineral density in HIV-infected patients
    Vieira, R.
    Oliveira, J.
    Lau, E.
    Madureira, P.
    Serrao, R.
    Sarmento, A.
    Pereira, J.
    Vaz, C.
    Costa, L.
    Carvalho, D.
    Freitas, P.
    ANTIVIRAL THERAPY, 2014, 19 : A35 - A35
  • [7] Low bone mineral density among HIV-infected patients in Brazil
    Chaba, Daniela Cardeal da Silva
    Soares, Lismeia R.
    Pereira, Rosa M. R.
    Rutherford, George W.
    Assone, Tatiane
    Takayama, Liliam
    Fonseca, Luiz A. M.
    Duarte, Alberto J. S.
    Casseb, Jorge
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2017, 59
  • [8] Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy
    Bruera, D
    Luna, N
    David, DO
    Bergoglio, LA
    Zamudio, J
    AIDS, 2003, 17 (13) : 1917 - 1923
  • [9] Reduced bone mineral density in HIV-infected patients:: prevalence and associated factors
    Cazanave, Charles
    Dupon, Michel
    Lavignolle-Aurillac, Valerie
    Barthe, Nicole
    Lawson-Ayayi, Sylvie
    Mehsen, Nadia
    Mercie, Patrick
    Morlat, Phillipe
    Thiebaut, Rodolphe
    Dabis, Francois
    AIDS, 2008, 22 (03) : 395 - 402
  • [10] Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy
    Brendel, K
    Legrand, M
    Taburet, AM
    Baron, G
    Goujard, C
    Mentré, F
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (03) : 373 - 383